research use only

Famotidine Histamine Receptor antagonist

Name: Famotidine
Brand: Selleck Chemicals
SKU: S2078
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.S2078

Famotidine (MK208) is a histamine H2–receptor antagonist with IC50 of 0.6 mM, commonly used to treat heartburn, GERD, ulcers, and other digestive conditions.

Famotidine Histamine Receptor antagonist Chemical Structure

Quality Control

Batch: S207801 DMSO]67 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.48%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.48

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Histamine Receptor Inhibitors	GSK2879552 Dihydrochloride JNJ-7777120 Mianserin HCl Ebastine Astemizole Ciproxifan Maleate Rupatadine Lafutidine Cloperastine hydrochloride Mizolastine

Solubility

In vitro
Batch:

DMSO : 67 mg/mL (198.54 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	2%DMSO 1 40%PEG300 2 5%TWEEN80 3 53%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.100mg/ml (0.30mM)	Taking the 1 mL working solution as an example, add 20 μL of 5 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 530 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	337.45	Formula	C₈H₁₅N₇O₂S₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	76824-35-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	MK208			SMILES	C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	H2 receptor

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05977998	RECRUITING	Gastric Adenocarcinoma; Carcinomatosis	M.D. Anderson Cancer Center	2023-09-08	PHASE2
NCT04488081	ACTIVE_NOT_RECRUITING	COVID-19	QuantumLeap Healthcare Collaborative	2020-07-31	PHASE2
NCT06819670	RECRUITING	Infantile Spasms; Infantile Epileptic Spasms Syndrome; West Syndrome	University of California, Los Angeles	2025-05-05	PHASE2
NCT06207305	RECRUITING	Metastatic Appendiceal Adenocarcinoma; Intraperitoneal Paclitaxel	M.D. Anderson Cancer Center	2024-01-30	PHASE1; PHASE2
NCT06241183	RECRUITING	Dyspepsia; GERD; Acid Reflux	Stony Brook University	2023-11-09	PHASE4
NCT07539961	NOT_YET_RECRUITING	Calcific Tendinitis	University Hospital Dubrava	2026-09-01

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):